| P50 | author | Lynn Rosenberg | Q55454936 |
| | Todd R Sponholtz | Q87712658 |
| | Lauren Wise | Q42811966 |
| | Elizabeth Hatch | Q43148948 |
| | Julie R Palmer | Q47709111 |
| P2093 | author name string | Lucile L Adams-Campbell | |
| P2860 | cites work | Oral contraceptives and the risk of endometrial cancer | Q57562355 |
| | Decreased Risk of Endometrial Cancer among Oral-Contraceptive Users | Q60727794 |
| | Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development | Q70162426 |
| | Protection against endometrial carcinoma by combination-product oral contraceptives | Q70209920 |
| | A prospective cohort study of oral contraceptives and cancer of the endometrium | Q71069390 |
| | Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA) | Q72130727 |
| | The Black Women's Health Study: a follow-up study for causes and preventions of illness | Q72168817 |
| | Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women | Q80394797 |
| | Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study | Q83328198 |
| | A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden | Q83569494 |
| | Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk | Q83893657 |
| | Therapeutic options for management of endometrial hyperplasia | Q26783569 |
| | Cancer statistics, 2015 | Q27860576 |
| | Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies | Q30049057 |
| | Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. | Q30413346 |
| | Long-term postmenopausal hormone therapy and endometrial cancer | Q33650188 |
| | Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study | Q34192784 |
| | Menopausal hormone therapy and risk of endometrial cancer | Q34345110 |
| | Endometrial cancer and hormone-replacement therapy in the Million Women Study | Q34415404 |
| | Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer | Q35510465 |
| | Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors | Q35568234 |
| | Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). | Q35926568 |
| | The epidemiology of endometrial cancer in young women | Q36047673 |
| | Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? | Q36189328 |
| | The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk | Q36465880 |
| | Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan | Q36608842 |
| | Type I and II endometrial cancers: have they different risk factors? | Q36977055 |
| | Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity | Q37330162 |
| | Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial | Q37353846 |
| | Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition | Q42852626 |
| | Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition | Q43238847 |
| | Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer | Q44648087 |
| | Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer | Q45126916 |
| | A prospective study of body size and breast cancer in black women. | Q47270427 |
| | Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. | Q51167827 |
| | Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. | Q52930339 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endometrial cancer | Q944777 |
| P304 | page(s) | 558-565 | |
| P577 | publication date | 2018-02-23 | |
| P1433 | published in | Cancer Epidemiology, Biomarkers & Prevention | Q326334 |
| P1476 | title | Exogenous Hormone Use and Endometrial Cancer in U.S. Black Women | |
| P478 | volume | 27 | |